{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:01:27Z","timestamp":1784667687896,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009109","name":"Bayer Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ekir.2026.106409","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:54:44Z","timestamp":1772672084000},"page":"106409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["External Control Augmentation Increases Estimates Precision for Finerenone plus Sodium-Glucose Cotransporter-2 Inhibitors"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6518-7254","authenticated-orcid":false,"given":"Sascha van","family":"Boemmel-Wegmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Zerck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Hartenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schuchhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Edfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo E.","family":"Farjat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8292-2014","authenticated-orcid":false,"given":"Michael","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106409_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jtho.2020.12.008","article-title":"Statistical considerations for subgroup analyses","volume":"16","author":"Wang","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ekir.2026.106409_bib2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s40471-022-00305-9","article-title":"External comparator groups derived from real-world data used in support of regulatory decision making: use cases and challenges","volume":"9","author":"Carrigan","year":"2022","journal-title":"Curr Epidemiol Rep"},{"key":"10.1016\/j.ekir.2026.106409_bib3","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/pds.4975","article-title":"Real-world evidence to support regulatory decision-making for medicines: considerations for external control arms","volume":"29","author":"Burcu","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ekir.2026.106409_bib5","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s43441-021-00302-y","article-title":"The use of external controls in FDA regulatory decision making","volume":"55","author":"Jahanshahi","year":"2021","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.ekir.2026.106409_bib6","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/pds.5141","article-title":"Methods for external control groups for single arm trials or long-term uncontrolled extensions to randomized clinical trials","volume":"29","author":"Seeger","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ekir.2026.106409_bib7","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106409_bib8","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106409_bib9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106409_bib10","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106409_bib11","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106409_bib12","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1111\/dom.15194","article-title":"Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019\u20132020","volume":"25","author":"Nicholas","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2026.106409_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2026.106409_bib14","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2026.106409_bib15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106409_bib16","first-page":"1681","article-title":"Reduction in urinary albumin-to-creatinine ratio (UACR) in people with CKD and type 2 diabetes initiating finerenone: a comedication subgroup analysis from the FOUNTAIN platform","volume":"35","author":"Kovesdy","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106409_bib17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.106409_bib19","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/cpt.1633","article-title":"Nonrandomized real-world evidence to support regulatory decision making: process for a randomized trial replication project","volume":"107","author":"Franklin","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ekir.2026.106409_bib20","author":"Sun"},{"key":"10.1016\/j.ekir.2026.106409_bib21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/pst.2352","article-title":"An evolutionary algorithm for the direct optimization of covariate balance between nonrandomized populations","volume":"23","author":"Privitera","year":"2024","journal-title":"Pharm Stat"},{"key":"10.1016\/j.ekir.2026.106409_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1017\/pan.2019.11","article-title":"Why propensity scores should not be used for matching","volume":"27","author":"King","year":"2019","journal-title":"Polit Anal"},{"key":"10.1016\/j.ekir.2026.106409_bib23","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1080\/01621459.2012.703874","article-title":"Using mixed integer programming for matching in an observational study of kidney failure after surgery","volume":"107","author":"Zubizarreta","year":"2012","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ekir.2026.106409_bib24","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.ekir.2026.106409_bib25","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1161\/CIRCULATIONAHA.125.073235","article-title":"Non-randomized database analyses to complement randomized clinical trials: promising approaches for cardiovascular medicine","volume":"151","author":"Schneeweiss","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106409_bib26","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/CIRCULATIONAHA.120.051718","article-title":"Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE initiative","volume":"143","author":"Franklin","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106409_bib27","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMp2113319","article-title":"Methods of public health research \u2013 strengthening causal inference from observational data","volume":"385","author":"Hern\u00e1n","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106409_bib28","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106409_bib29","doi-asserted-by":"crossref","first-page":"101000","DOI":"10.1016\/j.conctc.2022.101000","article-title":"Augmenting control arms with real-world data for cancer trials: hybrid control arm methods and considerations","volume":"30","author":"Tan","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.ekir.2026.106409_bib30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12874-024-02383-3","article-title":"Incorporating external controls in the design of randomized clinical trials: a case study in solid tumors","volume":"24","author":"Damone","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ekir.2026.106409_bib31","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/neuonc\/noae005","article-title":"Leveraging external control data in the design and analysis of neuro-oncology trials: pearls and perils","volume":"26","author":"Polley","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ekir.2026.106409_bib32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/jamacardio.2024.3782","article-title":"Estimated long-term benefits of finerenone in heart failure: a prespecified secondary analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Vaduganathan","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ekir.2026.106409_bib33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106409_bib34","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1017\/cts.2023.559","article-title":"Challenges and strategies for recruitment of minorities to clinical research and trials","volume":"7","author":"Fisher-Hoch","year":"2023","journal-title":"J Clin Transl Sci"},{"key":"10.1016\/j.ekir.2026.106409_bib35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc17-1414","article-title":"Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes","volume":"41","author":"Montvida","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106409_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.23876\/j.krcp.2017.36.1.3","article-title":"Medical big data: promise and challenges","volume":"36","author":"Lee","year":"2017","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.ekir.2026.106409_bib37","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.ekir.2023.05.008","article-title":"Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)","volume":"8","author":"Herrington","year":"2023","journal-title":"Kidney Int Rep"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926026409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926026409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:05:30Z","timestamp":1784664330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926026409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2468024926026409"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106409","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"External Control Augmentation Increases Estimates Precision for Finerenone plus Sodium-Glucose Cotransporter-2 Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106409"}}